Novavax Dirección

Dirección controles de criterios 2/4

El CEO de Novavax's es John Jacobs , nombrado en Jan 2023, tiene una permanencia de 1.33 años. compensación anual total es $7.30M, compuesta por 9.1% salario y 90.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.031% de las acciones de la empresa, por valor de $200.51K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 3.8 años, respectivamente.

Información clave

John Jacobs

Chief Executive Officer (CEO)

US$7.3m

Compensación total

Porcentaje del salario del CEO	9.1%
Permanencia del CEO	1.3yrs
Participación del CEO	0.03%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

May 14

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

May 07

Novavax: Another Day Older And Deeper In

Mar 02

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Mar 02

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Mar 01

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Feb 23

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Sep 06

Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook

Mar 05

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de John Jacobs en comparación con los beneficios de Novavax?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$399m
Dec 31 2023	US$7m	US$663k	-US$545m

Compensación vs. Mercado: La compensación total ($USD7.30M) de John está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.66M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de John con los resultados de la empresa.

CEO

John Jacobs (56 yo)

1.3yrs

Permanencia

US$7,301,009

Compensación

Mr. John Charles Jacobs, M.B.A., serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
John Jacobs	President	1.3yrs	US$7.30m	0.034% $ 618.4k
John Trizzino	President & COO	less than a year	US$1.88m	0.020% $ 363.9k
James Kelly	Executive VP	2.8yrs	US$1.50m	0.0095% $ 172.8k
Mark Casey	Executive VP	less than a year	US$1.53m	sin datos
Stanley Erck	Advisor	1.3yrs	US$4.60m	0.024% $ 443.2k
Filip Dubovsky	President of Research & Development	3.9yrs	US$1.93m	0.028% $ 506.8k
Richard Crowley	Executive VP & COO	1.3yrs	sin datos	sin datos
Troy Morgan	Senior VP & Chief Compliance Officer	no data	sin datos	sin datos
Erika Trahan	Associate Director of Investor & Public Relations	6.1yrs	sin datos	sin datos
Ian Watkins	Executive VP & Chief Human Resources Officer	less than a year	sin datos	sin datos
Silvia Taylor	Executive VP and Chief Corporate Affairs & Advocacy Officer	2.3yrs	sin datos	sin datos
Elaine O'Hara	Executive VP & Chief Strategy Officer	1.3yrs	sin datos	0.010% $ 185.1k

1.3yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NVAX no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Jacobs	President	1.3yrs	US$7.30m	0.034% $ 618.4k
David Mott	Independent Director	3.9yrs	US$187.53k	0.036% $ 656.6k
Richard Douglas	Independent Director	14.3yrs	US$189.53k	0.031% $ 571.4k
Margaret McGlynn	Independent Director	3.4yrs	US$185.02k	0.0075% $ 136.3k
Gregg Alton	Independent Director	3.6yrs	US$175.28k	0.0075% $ 136.3k
Rachel King	Independent Director	5.5yrs	US$174.55k	0.013% $ 246.1k
Richard Rodgers	Independent Director	1.6yrs	US$191.78k	0.0075% $ 136.3k
James Young	Independent Chairman of the Board	14.1yrs	US$222.53k	0.055% $ 998.7k

3.8yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de NVAX se considera experimentada (3.7 años de antigüedad promedio).

Novavax Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

President of Research & Development recently sold US$384k worth of stock

President of Research & Development notifies of intention to sell stock

Novavax, Inc., Annual General Meeting, Jun 13, 2024

President of Research & Development exercised options and sold US$14k worth of stock

CEO & Director exercised options and sold US$171k worth of stock

Novavax, Inc. Announces Changes to Executive Leadership Team

Recent updates

President of Research & Development recently sold US$384k worth of stock

Consensus revenue estimates increase by 13%

President of Research & Development notifies of intention to sell stock

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

New major risk - Financial position

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

Novavax, Inc., Annual General Meeting, Jun 13, 2024

Consensus EPS estimates upgraded to US$0.55 loss

New minor risk - Profitability

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss

President of Research & Development exercised options and sold US$14k worth of stock

Consensus estimates of losses per share improve by 28%

Price target decreased by 20% to US$15.40

Novavax: Another Day Older And Deeper In

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Full year 2023 earnings: EPS and revenues miss analyst expectations

Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024

Consensus EPS estimates upgraded to US$0.39 loss, revenue downgraded

New minor risk - Share price stability

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

CEO & Director exercised options and sold US$171k worth of stock

Price target increased by 15% to US$23.25

Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older

Novavax, Inc. Announces Changes to Executive Leadership Team

No longer forecast to breakeven

New major risk - Shareholder dilution

Price target increased by 11% to US$24.50

Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024

Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022)

No longer forecast to breakeven

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

Forecast to breakeven in 2024

Consensus estimates of losses per share improve by 11%

Forecast to breakeven in 2024

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 12%

Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novavax, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Profitability

Consensus estimates of losses per share improve by 24%

New minor risk - Profitability

New major risk - Share price stability

Novavax's Nuvaxovid™? Receives Full Marketing Authorization in the Eu for the Prevention of Covid

Consensus EPS estimates fall by 35%

Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Midcap Index

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

No longer forecast to breakeven

Forecast to breakeven in 2025

Novavax, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 16% to US$39.33

Consensus EPS estimates upgraded to US$4.96 loss, revenue downgraded

Consensus revenue estimates decrease by 25%

Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook

No longer forecast to breakeven

Price target increased by 23% to US$68.33